Withdrawal of Antiepileptic Drugs in Patients with Low Grade and Anaplastic Glioma After Long-term Seizure Freedom: a Prospective Observational Study

Overview

Journal J Neurooncol

Publisher Springer

Date 2019 Feb 20

PMID 30778733

Citations 17

Authors

M Kerkhof

J A F Koekkoek

M J Vos

M J van den Bent

W Taal

T J Postma

J E C Bromberg

M C M Kouwenhoven

L Dirven

J C Reijneveld

M J B Taphoorn

Affiliations

Soon will be listed here.

Abstract

Background: When glioma patients experience long-term seizure freedom the question arises whether antiepileptic drugs (AEDs) should be continued. As no prospective studies exist on seizure recurrence in glioma patients after AED withdrawal, we evaluated the decision-making process to withdraw AEDs in glioma patients, and seizure outcome after withdrawal.

Methods: Patients with a histologically confirmed low grade or anaplastic glioma were included. Eligible patients were seizure free ≥ 1 year from the date of last antitumor treatment, or ≥ 2 years since the last seizure when seizures occurred after the end of the last antitumor treatment. Patients and neuro-oncologists made a shared decision on the preferred AED treatment (i.e. AED withdrawal or continuation). Primary outcomes were: (1) outcome of the shared decision-making process and (2) rate of seizure recurrence.

Results: Eighty-three patients fulfilled all eligibility criteria. However, in 12/83 (14%) patients, the neuro-oncologist had serious objections to AED withdrawal. Therefore, 71/83 (86%) patients were analyzed; In 46/71 (65%) patients it was decided to withdraw AED treatment. In the withdrawal group, 26% (12/46) had seizure recurrence during follow-up. Seven of these 12 patients (58%) had tumor progression, of which three within 3 months after seizure recurrence. In the AED continuation group, 8% (2/25) of patients had seizure recurrence of which one had tumor progression.

Conclusion: In 65% of patients a shared decision was made to withdraw AEDs, of which 26% had seizure recurrence. AED withdrawal should only be considered in carefully selected patients with a presumed low risk of tumor progression.

Citing Articles

Symptom management in isocitrate dehydrogenase mutant glioma.

Walbert T, Avila E, Boele F, Hertler C, Lu-Emerson C, van der Meer P Neurooncol Pract. 2025; 12(Suppl 1):i38-i48.

PMID: 39776527 PMC: 11703367. DOI: 10.1093/nop/npae088.

Maschio M, Perversi F, Maialetti A Front Neurol. 2024; 15:1480900.

PMID: 39722690 PMC: 11668670. DOI: 10.3389/fneur.2024.1480900.

Patient-Centered Management of Brain Tumor-Related Epilepsy.

Dorotan M, Tobochnik S Curr Neurol Neurosci Rep. 2024; 24(9):413-422.

PMID: 39017829 DOI: 10.1007/s11910-024-01360-z.

Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study.

van der Meer P, Dirven L, Fiocco M, Vos M, Kerkhof M, Kouwenhoven M J Neurooncol. 2023; 164(3):545-555.

PMID: 37755633 PMC: 10589365. DOI: 10.1007/s11060-023-04450-z.

Avila E, Tobochnik S, Inati S, Koekkoek J, McKhann G, Riviello J Neuro Oncol. 2023; 26(1):7-24.

PMID: 37699031 PMC: 10768995. DOI: 10.1093/neuonc/noad154.

References

Luyken C, Blumcke I, Fimmers R, Urbach H, Elger C, Wiestler O . The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia. 2003; 44(6):822-30. DOI: 10.1046/j.1528-1157.2003.56102.x. View

Klein M, Engelberts N, van der Ploeg H, Kasteleijn-Nolst Trenite D, Aaronson N, Taphoorn M . Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003; 54(4):514-20. DOI: 10.1002/ana.10712. View

Ortinski P, Meador K . Cognitive side effects of antiepileptic drugs. Epilepsy Behav. 2004; 5 Suppl 1:S60-5. DOI: 10.1016/j.yebeh.2003.11.008. View

Taphoorn M . Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol. 2004; 30(6 Suppl 19):45-8. DOI: 10.1053/j.seminoncol.2003.11.023. View

Specchio L, Beghi E . Should antiepileptic drugs be withdrawn in seizure-free patients?. CNS Drugs. 2004; 18(4):201-12. DOI: 10.2165/00023210-200418040-00001. View

Hildebrand J, Lecaille C, Perennes J, Delattre J . Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology. 2005; 65(2):212-5. DOI: 10.1212/01.wnl.0000168903.09277.8f. View

van den Bent M, Afra D, De Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K . Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005; 366(9490):985-90. DOI: 10.1016/S0140-6736(05)67070-5. View

Aktekin B, Apaydin Dogan E, Oguz Y, Senol Y . Withdrawal of antiepileptic drugs in adult patients free of seizures for 4 years: a prospective study. Epilepsy Behav. 2006; 8(3):616-9. DOI: 10.1016/j.yebeh.2006.01.018. View

Lossius M, Hessen E, Mowinckel P, Stavem K, Erikssen J, Gulbrandsen P . Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia. 2007; 49(3):455-63. DOI: 10.1111/j.1528-1167.2007.01323.x. View

10.

Chang E, Potts M, Keles G, Lamborn K, Chang S, Barbaro N . Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008; 108(2):227-35. DOI: 10.3171/JNS/2008/108/2/0227. View

11.

Ricard D, de Greslan T, Soussain C, Bounolleau P, Sallansonnet-Froment M, Delmas J . [Neurological damage of brain tumor therapy]. Rev Neurol (Paris). 2008; 164(6-7):575-87. DOI: 10.1016/j.neurol.2008.03.014. View

12.

Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A . Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg. 2009; 111(2):282-92. DOI: 10.3171/2009.2.JNS081132. View

13.

Taillandier L, Duffau H . Epilepsy and insular Grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus. 2009; 27(2):E8. DOI: 10.3171/2009.6.FOCUS09102. View

14.

Smits A, Duffau H . Seizures and the natural history of World Health Organization Grade II gliomas: a review. Neurosurgery. 2011; 68(5):1326-33. DOI: 10.1227/NEU.0b013e31820c3419. View

15.

Englot D, Berger M, Barbaro N, Chang E . Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011; 115(2):240-4. DOI: 10.3171/2011.3.JNS1153. View

16.

Weller M, Gorlia T, Cairncross J, van den Bent M, Mason W, Belanger K . Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011; 77(12):1156-64. PMC: 3265044. DOI: 10.1212/WNL.0b013e31822f02e1. View

17.

You G, Sha Z, Yan W, Zhang W, Wang Y, Li S . Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol. 2011; 14(2):230-41. PMC: 3266386. DOI: 10.1093/neuonc/nor205. View

18.

Kerkhof M, Dielemans J, van Breemen M, Zwinkels H, Walchenbach R, Taphoorn M . Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013; 15(7):961-7. PMC: 3688020. DOI: 10.1093/neuonc/not057. View

19.

Ruda R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C . Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol. 2013; 15(12):1739-49. PMC: 3829585. DOI: 10.1093/neuonc/not109. View

20.

Perucca E . Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013; 54 Suppl 9:97-104. DOI: 10.1111/epi.12452. View